Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
Bullboard Posts
User Avatar Image
(15)
•••
Comment by PinnacleXon Dec 19, 2019 3:51pm
78 Views
Post# 30474082

RE:RE:RE:RE:RE:Odd...

RE:RE:RE:RE:RE:Odd...
palinc2000 wrote: Sorry to hear that I hurt your feeling? What brought this about?
Disagreeing with your friend Luc and calling him out when needed does not warrant your comment.
Contrary to some here I have no relation personal or otherwise with Luc or anyone else at TH 

Maybe I should call him  to find out what next weeks PR will be about/

SPCEO1 wrote: Palinc2000 - did you once work for TH and did Luc fire you? Your venom towards him has always seemed to reflect something personal.
Bucknelly21 wrote: Palinic I know you are super unhappy with everything but he's a good guy, maybe not the right guy moving forward but he did save th 






atta boy palinic. He does get offended easily. He has personal meetings with that buck idiot from what we've heard aswell lol the whole board meets with bucknuts
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities